Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock

After Eli Lilly and Co LLY earlier announce the failure of its Alzeheimer’s candidate solanezumab, the entire Alzheimer's sector could feel the aftershocks. While some of the players have since recovered from early morning drops, a few are still in the red in early Wednesday afternoon.

Alzheimer's Treatment Stocks

Below are the players within the sector, and their subsequent stock movements at time of writing:

• AC Immune Ltd ACIU: Down 16.06 percent at $11.50.
• Alkermes Plc ALKS: Up 0.69 percent at $58.74.
• Anavex Life Sciences Corp. AVXL: Up 6.76 percent at $3.63.
• Biogen Inc BIIB: Down 3.94 percent at $305.59.
• Eli Lilly and Co: Down 10.76 percent at $67.82.
• Neuralstem, Inc. CUR: Up 3.81 percent at $0.270.
• Novartis AG (ADR) NVS: Up 0.98 percent at $68.76.
• Roche Holding Ltd. (ADR) RHHBY: Down 1.3 percent at $27.40.